Year: 2020
Type: article
Abstract: Tumor blood vessels have leaky and low blood flow properties, which lead to hypoxia and low nutrient levels in the tumor tissue area known as the tumor microenvironment (TME). We reported that the prolyl-hydroxylase (PHD) inhibitor Roxadustat normalized tumor blood vessels, improved tumor tissue perfusion, and re-oxygenated the tumor tissue. Recently, several PHD inhibitors including Roxadustat, Daprodustat, Molidustat, and Vadadustat, were evaluated in clinical trials and approved for treating renal anemia. In this study, we showed that PHD inhibitors reconstituted tumor blood vessels and improved the TME, and some agents exhibited differential effects on tumors in a mouse model.
Institutions: Osaka City University, Osaka Ohtani University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,000
Awards: Elucidation of anti-tumor mechanisms based on innate immune activation by PHD inhibitors and exploration of therapeutic targets, Elucidation of Molecular Mechanism of Mycobacterial Latency via Mycobacterial Membrane Vesicles, Enhancement of anti-tumor immunity by the promortion of the tumor infiltration of CD103+ dendritic cells, Angiogenesis in renal fibrosis
OpenAlex ID: W3010245832